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Abstract
Background: Computerised clinical decision support systems (CDSSs) are used widely to improve quality of
care and patient outcomes. This systematic review evaluated the impact of CDSSs in targeting specific aspects of
prescribing, namely initiating, monitoring and stopping therapy. We also examined the influence of clinical setting
(institutional vs ambulatory care), system- or user-initiation of CDSS, multi-faceted vs stand alone CDSS
interventions and clinical target on practice changes in line with the intent of the CDSS.
Methods: We searched Medline, Embase and PsychINFO for publications from 1990-2007 detailing CDSS
prescribing interventions. Pairs of independent reviewers extracted the key features and prescribing outcomes of
methodologically adequate studies (experiments and strong quasi-experiments).
Results: 56 studies met our inclusion criteria, 38 addressing initiating, 23 monitoring and three stopping therapy.
At the time of initiating therapy, CDSSs appear to be somewhat more effective after, rather than before, drug
selection has occurred (7/12 versus 12/26 studies reporting statistically significant improvements in favour of
CDSSs on = 50% of prescribing outcomes reported). CDSSs also appeared to be effective for monitoring therapy,
particularly using laboratory test reminders (4/7 studies reporting significant improvements in favour of CDSSs
on the majority of prescribing outcomes). None of the studies addressing stopping therapy demonstrated impacts
in favour of CDSSs over comparators. The most consistently effective approaches used system-initiated advice to
fine-tune existing therapy by making recommendations to improve patient safety, adjust the dose, duration or
form of prescribed drugs or increase the laboratory testing rates for patients on long-term therapy. CDSSs
appeared to perform better in institutional compared to ambulatory settings and when decision support was
initiated automatically by the system as opposed to user initiation. CDSSs implemented with other strategies such
as education were no more successful in improving prescribing than stand alone interventions. Cardiovascular
disease was the most studied clinical target but few studies demonstrated significant improvements on the
majority of prescribing outcomes.
Conclusion:  Our understanding of CDSS impacts on specific aspects of the prescribing process remains
relatively limited. Future implementation should build on effective approaches including the use of system-initiated
advice to address safety issues and improve the monitoring of therapy.
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Background
Computerised clinical decision support systems (CDSSs)
are espoused as powerful tools for influencing health care
provider performance to improve quality of care and
patient outcomes. As such, proprietary and locally devel-
oped systems have been used to target provider behaviour
across a range of clinical circumstances including preven-
tive, acute and chronic care and to target specific test
ordering and prescribing practices.
In their simplest form CDSSs provide narrative informa-
tion requiring further processing and analysis by provid-
ers before clinical decisions are made. However, CDSSs
have become increasingly sophisticated by matching
patient characteristics with computerised knowledge
bases and using algorithms to generate patient-specific
assessments or treatment recommendations. [1] CDSSs
support a range of prescribing practice activities relating
broadly to initiating therapy, including the judicious
selection of drug treatments, adhering to best practice care
and checking allergies and drug interactions. In addition,
CDSSs can target other aspects of the prescribing process,
namely monitoring (with dose adjustments) and stop-
ping or tapering therapy.
The most comprehensive systematic reviews in the field
[1,2] established the benefits of CDSSs in changing prac-
titioner performance and to a lesser extent, patient out-
comes. Garg et al [1] reviewed 100 randomised and non-
randomised studies of CDSSs across a broad range of clin-
ical targets including diagnosis, prevention, disease man-
agement, drug dosing and drug prescribing while the
Kawamoto et al [2] review was restricted to randomised
controlled trials (RCTs) but assessed the impact of both
electronic and non-electronic systems. Both reviews also
examined system and organisational features predicting
the success of decision support.
Notably, improved CDSS performance was associated
with systems prompting providers automatically (system-
initiated) rather than requiring providers to activate the
decision support themselves (user-initiated).[1]
Kawamoto et al also reported the benefits of computer-
ised over paper-based systems and those providing advice
within the clinical workflow and at the time and location
of decision-making.[2] A subsequent review has also dem-
onstrated systems implemented in hospital practice are
more effective in improving outcomes than those target-
ing chronic disease in ambulatory care.[3]
Other systematic reviews have taken a narrower prescrib-
ing focus and demonstrate CDSSs can reduce toxic drug
levels and time to achieving therapeutic control [4,5];
reduce medication errors [6,7]; change prescribing in
accordance with guideline recommendations and increase
diagnostic testing. [8]
In a more recent systematic review, Mollon et al[9] exam-
ined the effects of CDSSs on prescribing practices and
evaluated whether particular system features could predict
successful implementation, provider behaviour change or
improved patient outcomes. The review was restricted to
RCTs of computer generated advice (delivered in elec-
tronic or paper-based formats) and targeted decisions pre-
sented before drug therapies were chosen or directly after
drug selection had taken place. The authors noted few
high quality studies showed improvement in patient out-
comes and there was insufficient detail on system features
in the original studies to inform future CDSS design and
implementation. None of the reviews conducted to date
have examined the effects of CDSSs across all aspects of
the prescribing process nor addressed clinical targets and
how they may relate to the relative success of CDSSs.
Providers' information needs are likely to vary across clin-
ical targets and the therapeutic process (initiating, moni-
toring and stopping therapy), and it is highly likely that
some aspects of prescribing practice are more amenable to
change than others. Previous research has suggested phy-
sicians are more reluctant to change practice if advice is
perceived as threatening to professional auton-
omy.[10,11] Thus, recommendations attempting to influ-
ence initial therapeutic choices or suggestions to stop
long-standing treatment may be more difficult to change
than attempts to flag safety issues or to fine-tune existing
therapy. Further, prescribing involves a complex set of
behaviours and there is strong evidence demonstrating
the benefits of multi-faceted, compared with single strat-
egy approaches to prescriber behaviour change. [12-14]
Therefore, the objective of this systematic review is to
examine the impact of CDSSs in targeting specific aspects
of prescribing, namely initiating treatment (before and
after drug selection has taken place), monitoring patients
on existing therapy and stopping treatment. Further,
within each domain, we will explore whether some of the
key technical and organisational features shown to be
effective in previous CDSS reviews change practice in line
with the intent of the CDSS, namely system versus user-
initiated advice, CDSSs implemented in institutional set-
tings versus ambulatory care, and multi-faceted versus
stand alone CDSS interventions. Finally, we will explore
the clinical areas targeted in the CDSS interventions.
Methods
Hypotheses Tested
We hypothesised that CDSSs for prescribing, where advice
is generated and delivered electronically, are more likelyBMC Health Services Research 2009, 9:154 http://www.biomedcentral.com/1472-6963/9/154
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to change prescribing practice in line with the intent of the
CDSS when decision support is:
• Provided to fine-tune existing therapy compared
with recommendations to influence initial drug
choices or cease long-standing therapy.
Within the various prescribing domains we also hypothe-
sised that CDSS is more likely to change prescribing prac-
tice in line with the intent of the CDSS when decision
support is:
￿ Implemented in institutional (inpatient) settings
compared with ambulatory care
￿ System-initiated compared with user-initiated
￿ Implemented with other intervention strategies
compared with implemented alone.
In addition, we were interested in exploring the clinical
areas targeted in CDSS interventions. While it is unlikely
there would be sufficient studies to test a formal hypothe-
sis relating to clinical target, we aimed to document the
clinical targets within prescribing domain and establish if
computerised CDSS is more effective in specific clinical
areas.
Studies Eligible for Review
We included English-language studies, published since
1990, reporting RCTs and strong quasi-experiments (non-
randomised studies with comparison groups or inter-
rupted time series designs with or without comparison
groups). We stipulated the studies had to: compare the
performance of computerised CDSS to routine care and/
or paper-based decision support; provide information
applicable to a specific patient that is reviewed by a pro-
vider at the time of prescribing (e.g. provide advice to pre-
scribe a particular drug, to monitor a drug or adjust the
dose, or to perform laboratory tests related to safe pre-
scribing); generate and deliver information to the pro-
vider in electronic formats; and report data on at least one
outcome relating to initiating, monitoring or stopping
therapy (Table 1).
Studies were excluded if the CDSS targeted only medical
students, pharmacists or nurses, interventions were based
around hypothetical scenarios rather than actual clinical
practice, and the advice provided by CDSS was feedback
about groups of patients (e.g. audit activities). Further
studies not undertaking statistical analyses and/or report-
ing only patient outcomes (e.g. quality of life, satisfaction
with care, greater physical activity levels) or cost data were
also excluded. A list of excluded studies is available on
request from the authors.
Study Identification
We searched Medline (1990 - November Week 3, 2007),
PreMedline (30 November, 2007), Embase (1990 - Week
47, 2007), CINAHL (1990 - November Week 4, 2007) and
PsycINFO (1990 - November Week 4, 2007). We com-
bined keywords and subject headings to identify compu-
ter-based decision support (e.g. decision support systems
clinical, decision making computer assisted), medicines use
(e.g. prescription drug, drug utilization) and medical practice
(e.g. physicians practice patterns, medical practice). We also
searched INSPEC (November 2007) and the Cochrane
Database of Systematic Reviews (November 2007) includ-
ing reviews and protocols published under the Effective
Practice and Organisation of Care Group (EPOC). Finally,
we hand-searched the reference lists of retrieved articles
and reviews. Additional File 1 details the full search strat-
egy.
Table 1: Definitions and examples of initiating, monitoring and stopping therapy
Initiating Therapy Provides suggestions on which drug to prescribe (or not to prescribe) when a new course of therapy is started.
Examples:
Prescribe a cholesterol lowering medication for patients with LDL > 130 mg/dL
Administer influenza vaccination
Do not prescribe long-acting benzodiazepines for elderly patients
Suggestions may be presented to the physician before choosinga drug (e.g. patient's cholesterol level triggers an alert 
recommending the use of statins) or after making a prescribing choice(e.g. drug interaction alert may prompt a change in 
medicine selected).
Monitoring Provides suggestions for patients on continuing drug therapy (i.e. past the initial prescribing decision).
Examples:
Increase or decrease dose for patients on existing therapy (e.g. inhaler dose for the prevention of asthma)
Therapeutic drug monitoring (e.g. laboratory tests to avoid drug toxicity)
Titration to target (e.g. INR range and warfarin dosing)
Stopping Therapy Guidance suggesting that a particular medication could be stopped or doses tapered with a view to stopping.
Examples:
Discontinuation of long-acting benzodiazepines in elderly patients receiving this drugBMC Health Services Research 2009, 9:154 http://www.biomedcentral.com/1472-6963/9/154
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Pairs of reviewers evaluated independently the study titles
and abstracts identified in the search. Full-text articles
were retrieved if any reviewer considered a citation poten-
tially relevant. The studies were further assessed for their
relevance using a screening tool based on study design,
intervention target and type of intervention.
Data Extraction
Studies deemed eligible for review underwent data extrac-
tion by pairs of reviewers independent of one another
(AM and IH, IH and SP). Disagreements were resolved by
discussion to reach consensus. We developed a data
extraction instrument based on checklists used in previ-
ous systematic reviews [1,13-15] but refined for the spe-
cific aims of this study. We extracted the following
information: study objectives, clinical setting (ambulatory
or institutional care), details of decision support interven-
tion (e.g. system- or user-initiated, multi-faceted or CDSS
alone, clinical target). Given the lack of uniformity in rela-
tion to terminology about prompts, alerts and reminders
we extracted details as they were reported in the manu-
scripts. We recorded details of the study design (including
the unit of intervention, comparison groups or measures,
group assignment, statistical analyses), participant num-
bers, outcomes of interest and results pertaining to these
outcomes.
Quality Assessment
Two reviewers (JR and DN) rated experimental and quasi-
experimental studies for methodological quality on a 10-
point scale consisting of five potential sources of bias (as
described by Garg and colleagues [1]). The items used to
assess study quality are described along with the out-
comes of this assessment in the results section. We also
noted whether statistical analyses were adjusted for clus-
tering (this was not part of the Garg assessment form).
Reporting
Due to heterogeneity in study methodology, comparison
groups, setting, intervention targets, and outcomes, we
could not use traditional meta-analytic approaches to
combine individual study results.
The studies in this review differed substantially in the type
and number of outcomes reported to measure interven-
tion impacts. In particular, clinical outcomes are not
reported across all studies, most likely due to the short-
term nature of the trials. This review only reports on the
impact of CDSSs on measures relating to prescribing and
includes laboratory or monitoring tests relevant for the
safe and appropriate use of particular medicines. While
these are intermediate outcomes, where studies have dem-
onstrated the use of a particular drug leads to improve-
ments in important patient outcomes, changes in
prescribing consistent with this evidence are likely to be a
reasonable surrogate for patient outcomes. We do, how-
ever, detail additional outcomes and provide a more
extensive description of our research methods in a related
report entitled 'Improving the uptake of evidence-based
drug information and decision support' http://
www.nps.org.au.
Outcomes in this review are summarised separately for
each study and coded according to the following scheme:
￿ "+ (NS)": intervention favoured CDSS (prescribing
was more consistent with the intentions of the CDSS)
but was not statistically significant;
￿ "- (NS)": intervention favoured the comparison
group (prescribing of comparison groups was more
consistent with the intentions of the CDSS) but was
not significant;
￿ "++": intervention favoured CDSS (prescribing was
more consistent with the intentions of the CDSS) and
was statistically significant;
￿ "- -": intervention favoured the comparison group
(prescribing of comparison groups was more consist-
ent with the intentions of the CDSS) and was statisti-
cally significant;
￿ "0": no difference between groups
￿ "U": this code was used where it was difficult to
ascertain the direction of the effect (usually due to lack
of information).
Individual studies were stratified according to prescribing
domain. Within domain we also categorised studies by
clinical area. Studies appear more than once if they
address decision support across more than one prescrib-
ing domain (e.g. initiating and monitoring therapy) or
report prescribing outcomes across more than one clinical
area. In the latter case, only the prescribing outcomes per-
tinent to the specific clinical area are presented in each cat-
egory.
We summarised studies in the manuscript by reporting
whether they demonstrated at least one positive prescrib-
ing outcome (general trend in favour of CDSS) and statis-
tically significant improvements in favour of CDSS on the
majority (≥ 50%) of prescribing outcomes (as used by
Garg and colleagues [1]). We chose to report general
trends as well as significant results given the likelihood
some studies were underpowered to detect statistically sig-
nificant differences in outcomes. Additional File 2 and
Additional File 3 detail results for four summary meas-
ures: at least one outcome in favour of CDSS; majority ofBMC Health Services Research 2009, 9:154 http://www.biomedcentral.com/1472-6963/9/154
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prescribing outcomes in favour of CDSS; at least one sta-
tistically significant prescribing outcome; and statistically
significant improvement on the majority of prescribing
outcomes.
Results
Characteristics of Included Studies (56 studies)
We screened the titles and abstracts of 7,243 articles and
reviewed 372 full-text articles. Fifty-six articles were
included in the review (Figure 1). Table 2 details the char-
acteristics of these studies.
Most studies (n = 38) focussed on decision support at the
time of initiating therapy (26 before and 12 after drug
selection), 23 on monitoring treatment and three on stop-
ping therapy. Most studies (n = 39) were undertaken in
North America, 35 targeted physicians exclusively and 21
targeted physicians with medical students and/or other
health care professionals such as nurses, nurse practition-
ers, pharmacists and physician assistants.
The majority of studies (n = 39) used system-initiated
decision support and 37 studies were conducted in ambu-
latory care (hospital outpatients, Veterans' Medical Cen-
tres, Health Maintenance Organisations), 16 in
institutional care (hospital inpatient, long-term care) and
three across both settings. Nineteen were multi-faceted in
that clinicians received combinations of academic detail-
ing, audit and feedback, didactic lectures and written
guidelines in addition to decision support.
Cardiovascular disease management was the most com-
mon clinical focus (n = 19). Other clinical areas included
anticoagulant therapy (n = 12), antibiotic prescribing (n =
9), vaccinations (n = 9), respiratory conditions such as
asthma and chronic obstructive pulmonary disease (n =
Table 2: Characteristics of included studies
Characteristic Characteristic Detail Studies (N = 56) References
Prescribing Domain* Initiating
Before drug selection 26 [16-41]
After drug selection 12 [42-53]
Monitoring 23 [20,35,36,39,49,54-71]
Stopping 3 [39,42,61]
Geographic Setting North America 39 [16-18,20,21,23,27-30,32,33,35-45,47,49-59,62,65-67]
Europe 15 [19,22,24-26,31,34,46,48,61,63,64,68-70]
Other 2 [60,71]
Target Physicians 35 [19-21,24-27,29-34,37,39,42,44-48,56,57,59-69,71]
Physicians/other health care professionals 21 [16-18,22,23,28,35,36,38,40,41,43,49-55,58,70]
Initiation of CDSS System initiated 39 [16,18,20-30,32,33,35-37,40-53,58,60,62,63,66,67,70]
User initiated 14 [17,31,34,54-57,59,61,64,65,68,69,71]
Mixed/Unclear 3 [19,38,39]
Clinical Setting Ambulatory 37 [16-20,22-28,31,32,35-39,41-43,46,48,51-54,58,59,61-
64,67-69]
Institutional 16 [21,29,30,33,34,44,45,47,49,50,55-57,65,66,71]
Both 3 [40,60,70]
Implementation strategy CDSS only 37 [17,21,22,27-29,34,36,37,40-57,59-65,68,69,71]
Multi-faceted 19 [16,18-20,23-26,30-33,35,38,39,58,66,67,70]
Clinical Area* Cardiovascular disease 19 [16-22,24,26,28,31-33,35,37,38,46,62,67]
Antibiotic therapy 9 [25,34,44,46,47,50,52,53,56]
Vaccinations 9 [17,20,21,33,36,38-41]
Respiratory conditions 9 [22,39,46,48,52,57,64,67,71]
Anticoagulant therapy 12 [20,21,29,33,54,55,59,63,65,68-70]
Elderly (multiple conditions and drugs) 4 [42,43,45,49]
Osteoporosis 2 [23,33]
Other 11 [20,27,30,36,51,52,58,60,61,66,67]
* Studies are represented more than once across categories if the intervention focused on more than one areaBMC Health Services Research 2009, 9:154 http://www.biomedcentral.com/1472-6963/9/154
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9), osteoporosis (n = 2) and prescribing for the elderly (n
= 4). Fifteen studies addressed more than one clinical
area.
Methodological Quality
Table 3 details the outcomes of the quality assessment.
Fifty of the 56 trials were RCTs, six were quasi-experi-
ments, five of which were interrupted time series designs.
Fifty studies used random or quasi-random allocation of
study groups, 20 reported randomisation by cluster (to
minimise contamination) and 24 accounted for clustering
in statistical analyses. Thirty six studies reported no base-
line differences between study groups or made the appro-
priate statistical adjustments to account for baseline
differences and 53 used objective study outcomes or sub-
jective outcomes with blinded assessment. Fifty trials
included at least 90% of baseline participants in final data
analyses. On the 10-point methods scale, the mean study
quality score was 7.9 (SD 1.9) with a range of 4 to 10.
Impact of CDSSs according to Prescribing Domain
Table 4 summarises the number of studies reporting at
least one positive outcome and statistically significant
improvement in favour of the CDSS on the majority (≥
50%) of prescribing outcomes. Additional File 4, Addi-
tional File 5, Additional File 6 and Additional File 7 dis-
play the key features of individual interventions, outcome
measures, quality scores and results, organised by the
study's primary clinical focus.
Initiating Treatment (38 studies) [16-41]
Overall, 36 studies demonstrated at least one positive pre-
scribing outcome in favour of CDSSs, and 19 reported sig-
nificant improvements on the majority of outcomes.
Before Drug Selection (26 studies)
Almost all studies (n = 24) showed improvements in at
least one outcome and 12 demonstrated significant
improvements on the majority of outcomes. Importantly,
one study involving preventive care recommendations for
increased use of angiotensin converting enzyme (ACE)
inhibitors [33] found the CDSS was significantly inferior
to its comparator on at least one outcome measure.
Nineteen of the 20 system-initiated decision support
interventions showed improvements in at least one out-
come and 12 demonstrated significant improvements on
the majority of outcomes. Two of the three user-initiated
systems had a positive effect on at least one outcome but
none demonstrated statistically significant improve-
ments.
All but two of the 20 studies conducted in ambulatory
care demonstrated at least one positive outcome in favour
of CDSS. However, only eight demonstrated significant
improvements in the majority of outcomes. All five of the
studies conducted in institutional care reported at least
one positive outcome in favour of CDSSs, and three dem-
onstrated statistically significant improvements in the
majority of measures.
Multi-faceted interventions did not appear to have any
advantage over interventions using CDSS alone (with 5 of
15 and 7 of 11 reporting statistically significant results on
the majority of outcomes respectively).
Cardiovascular disease was the most common clinical tar-
get for CDSS interventions, followed by vaccinations. Six-
teen studies addressed aspects of cardiovascular disease
management, such as primary and/or secondary preven-
tion. However, only four demonstrated significant posi-
tive CDSS impacts on the majority of outcomes measured.
All four used system-initiated advice to prompt physicians
about the therapeutic management of patients deter-
Process of study inclusion for the systematic review Figure 1
Process of study inclusion for the systematic review. * 
8 Studies provided data relevant to more than one prescrib-
ing domain.BMC Health Services Research 2009, 9:154 http://www.biomedcentral.com/1472-6963/9/154
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mined to be 'at risk' of cardiovascular events.
[21,24,26,28] Five of the nine studies targeting vaccina-
tions demonstrated statistically significant benefits in
favour of CDSS for the majority of outcomes
[20,21,36,40,41], and they too used system-initiated
advice to increase vaccination rates. There were too few
studies across the other clinical domains to draw any con-
clusions about the impact of CDSS in specific clinical
areas.
After Drug Selection (12 studies) [42-53]
All twelve studies reported improvements in at least one
outcome and seven demonstrated favourable results in
favour of CDSSs on the majority of outcomes. All of the
studies used system-initiated decision support. Four of the
five studies conducted in institutional care demonstrated
significant improvements in the majority of outcomes
and three of the seven studies conducted in ambulatory
care demonstrated significant improvements in the
majority of outcomes. None of the interventions in this
category were multi-faceted.
All six studies examining the effect of CDSS on antibiotic
prescribing reported at least one positive outcome, how-
ever, four studies demonstrated significant impacts on the
majority of outcomes. In each case, the intervention
involved system-initiated advice to target the rational use
of specific antibiotics.[44,47,50,53] Four studies evalu-
ated the effectiveness of CDSS for prescribing in the eld-
erly. Two demonstrated significant improvements in the
majority of outcomes and both studies focussed specifi-
cally on safety issues.[43,45] Based on patient specific
information, the first intervention customised initial dos-
ing recommendations for sedatives, neuroleptics, anti-
emetics and skeletal muscle relaxants. [45] The second
used alerts to prompt physicians after prescribing a partic-
ular medication to consider alternative therapy. [43]
Monitoring Patients on Existing Therapy (23 studies) 
[20,35,36,39,49,54-71]
Eighteen studies demonstrated positive results on at least
one outcome, and eight reported statistically significant
results in favour of CDSS on the majority of outcomes.
Five studies used CDSSs to advise on maintenance pre-
scribing, such as dose changes, in chronic therapy for
drugs including statins, anti-hypertensives, and asthma
medications. Twelve studies used dose calculators, eight
of which related to warfarin therapy and the remaining
studies investigated prescribers' responses to prompts for
laboratory tests, such as liver function tests, for a range of
medicines; one of these measured adherence to a warfarin
monitoring schedule.
Nine of the 11 system-initiated decision support interven-
tions showed improvements in at least one outcome and
six demonstrated significant improvements on the major-
Table 3: Quality assessment
Item n (%)
1. Method of allocation of study groups
2 = Random 48 (86)
1 = Quasi-random 2 (4)
0 = Selected concurrent controls 6 (11)
2. Unit of allocation
2 = Cluster (e.g. practice) 20 (36)
1 = Physician 13 (23)
0 = Patient 23 (41)
3. Presence of baseline differences between groups
2 = No baseline differences present or appropriate statistical adjustments made 36 (64)
1 = Baseline differences present and no statistical adjustments made 6 (11)
0 = Baseline characteristics not reported 14 (25)
4. Objectivity of outcome measures
2 = Objective outcomes or subjective outcomes with blinded assessment 53 (95)
1 = Subjective outcomes with no blinding but clearly defined assessment criteria 3 (5)
0 = Subjective outcomes with no blinding and poorly defined 0 (0)
5. Completeness of follow-up for appropriate unit of analysis
2 = >90% 50 (89)
1 = 80-90% 2 (4)
0 = <80% 4 (7)BMC Health Services Research 2009, 9:154 http://www.biomedcentral.com/1472-6963/9/154
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ity of outcomes. Nine of the 11 user-initiated systems had
a positive effect on at least one outcome but only two
demonstrated significant improvements on the majority
of outcomes.
Decision support interventions undertaken in institu-
tional care appeared to perform somewhat better than
those conducted in ambulatory care (3 of 7 versus 4 of 14
demonstrated the majority of outcomes were statistically
significant in favour of CDSS respectively).
We did not find any differences in the effectiveness of
multifaceted interventions versus CDSS only (with 2 of 7
and 6 of 16 reporting statistically significant results on the
majority of outcomes respectively).
All nine studies involving warfarin (anticoagulant) ther-
apy reported at least one positive outcome. Only two of
these demonstrated significant improvements in the
majority of outcomes. There were too few studies across
the other clinical domains to draw any conclusions about
the impact of CDSS in specific clinical areas. However,
there was some evidence to support CDSS in the realm of
reminders for laboratory tests with four of the seven stud-
ies reporting statistically significant results favouring
CDSS on the majority of outcomes. All of the effective
studies used system-initiated advice to increase therapeu-
tic monitoring of a range of drugs. [36,58,60,66]
Stopping Treatment (3 studies) [39,42,61]
Studies in this domain were too few to draw any specific
conclusions relating to our hypotheses. Two studies were
conducted in institutional care. One addressed stopping
ipratropium therapy and found the intervention inferior
to standard care (although the result was not statistically
significant).[39] The second hospital-based study
Table 4: Studies reporting at least one positive outcome and ≥ 50% significant outcomes in favour of CDSS
Before Drug Selection 
(n = 26) n/N (%)
After Drug Selection 
(n = 12) n/N (%)
Monitoring
(n = 23) n/N (%)
At least one 
positive 
outcome
≥ 50% 
statistically 
significant 
outcomes
At least one 
positive 
outcome
≥ 50% 
statistically 
significant 
outcomes
At least one 
positive 
outcome
≥ 50% 
statistically 
significant 
outcomes
Overall 24/26 (92) 12/26 (46) 12/12 (100) 7/12 (58) 18/23 (78) 8/23 (35)
Initiation of 
CDSS
System 19/20 (95) 12/20 (60) 12/12 (100) 7/12 (58) 9/11 (82) 6/11 (55)
User 2/3 (67) 0/3 (0) NA NA 9/11 (82) 2/11 (18)
Mixed/Unclear 3/3 (100) 0/3 (0) NA NA 0/1 (0) 0/1 (0)
Clinical Setting
Institutional 5/5 (100) 3/5 (60) 5/5 (100) 4/5 (80) 6/7(86) 3/7 (43)
Ambulatory Care 18/20 (90) 8/20 (40) 7/7 (100) 3/7 (43) 10/14 (71) 4/14 (29)
Both 1/1 (100) 1/1 (100) NA NA 2/2 (100) 1/2 (50)
Mode of 
Delivery
Multi-faceted 13/15 (87) 5/15 (33) NA NA 5/7 (71) 2/7 (29)
CDSS only 11/11(100) 7/11 (64) 12/12 (100) 7/12 (58) 13/16 (81) 6/16 (38)
Clinical Area
Cardiovascular 13/16 (81) 4/16 (25) 1/1 (100) 0/1 (0) 2/3 (67) 1/3 (33)
Antibiotics 2/2 (100) 1/2 (50) 6/6 (100) 4/6 (67) 1/1 (100) 0/1 (0)
Vaccinations 8/9 (89) 5/9 (56) NA NA NA NA
Respiratory 1/2 (50) 0/2 (0) 3/3 (100) 1/3 (33) 2/5 (40) 1/5 (20)
Anticoagulants 3/3 (100) 2/3 (67) NA NA 9/9 (100) 2/9 (22)
Elderly NA NA 4/4 (100) 2/4 (50) 0/1 (0) 0/1 (0)
Osteoporosis 2/2 (100) 1/2 (50) NA NA NA NA
Other 3/4 (75)a 3/4 (75)a 2/2 (100)b 2/2 (100)b 5/6 (83)c 4/6 (67)c
a Other clinical areas include: salicylates or paracetamol in patients with history of GI bleed; erythropoietin low Hb; HIV medications; various 
medications
b Other clinical areas include: various medications interacting with warfarin; various conditions in children (e.g. croup, otitis media)
c Other clinical areas include: hormone treatment for infertility; etretinate for psoriasis; HIV medications; various conditions (e.g. epilepsy, gout, 
diabetes).BMC Health Services Research 2009, 9:154 http://www.biomedcentral.com/1472-6963/9/154
Page 9 of 14
(page number not for citation purposes)
involved patients undergoing ovarian stimulation for
infertility using software to predict whether additional
cycles of ovulatory stimulants should be administered
[61] however the impact on the prescribing outcome
(number of cancelled cycles) was unclear. There were no
statistically significant changes in any of the prescribing
outcomes for the third study that examined alerts relating
to discontinuing potentially inappropriate medications in
the elderly (e.g. NSAIDs and benzodiazepines). [42]
Discussion
The current review explored the impact of CDSSs on key
decision points in the prescribing process and highlights
the diversity of studies, intervention targets and methods
reported to date. While the range and variety of studies
adds great breadth to the field it makes synthesis challeng-
ing and creates difficulties in providing clear guidance on
where CDSSs are likely to be most effective. We did how-
ever find some general trends supporting the effectiveness
of CDSSs across specific aspects of the prescribing process.
Key Findings
In the realm of initiating therapy we found some indica-
tion of greater effectiveness of CDSSs after, rather than
before, drug selection. The effective interventions imple-
mented after drug selection had taken place all used sys-
tem-initiated advice to flag key safety issues (such as
alerting providers to high severity drug interactions, con-
traindications with other medications and cautions
against prescribing particular medications for the elderly)
or provided quality use of medicine messages (such as
alterations to durations of therapy and/or form of pre-
scribed drugs). This supports our hypothesis that it is eas-
ier to influence practice in relation to fine-tuning therapy
rather than attempting to influence initial therapeutic
choices. We also found some evidence to support the ben-
efits of CDSSs in increasing the laboratory testing rates for
patients on long-term therapy including cardiovascular
and respiratory medicines. Further, consistent with previ-
ous reviews, system-initiated CDSSs appeared to be more
effective than user-initiated systems as did CDSSs imple-
mented in institutional as opposed to ambulatory set-
tings.
We did not however find any evidence to support the
notion that CDSSs implemented with other strategies
such as education are more successful in changing pre-
scribing than stand alone interventions. It is notable that
few studies addressed stopping or tapering therapy, none
of which demonstrated impacts in favour of CDSSs over
comparators on the majority of outcomes. While many of
the interventions addressed the prevention and manage-
ment of cardiovascular disease only a small number of
these demonstrated significant improvements on the
majority of prescribing outcomes. Studies were too few in
the other clinical domains to draw firm conclusions about
the benefits of CDSS in managing specific clinical areas.
Limitations
This review had a number of limitations. Despite our
intensive efforts, the collection of intervention studies is
likely to be incomplete as some evaluations may not be
available in the public domain, others may be published
outside the peer-reviewed academic literature or pub-
lished in languages other than English. Of the available
studies, it was difficult to synthesise the material pre-
sented due to use of ambiguous terminology and more
particularly there was little detail provided about the way
in which the CDSSs were integrated into existing and/or
new software systems. We did however manage to extract
some key information about system and organisational
factors demonstrated in previous reviews to influence out-
comes.
While our review is not unique to the field, the overlap
between studies in our review and others published previ-
ously is surprisingly small (see Additional File 8). This is
due primarily to the variability in search terms and dates
and more specifically inclusion and exclusion criteria (for
example, RCTs versus RCTs plus quasi-experiments; phy-
sicians only versus all providers; prescribing only versus
the full spectrum of clinical care; computerised advice
delivered in electronic formats versus other electronic
and/or paper-based formats). Prescribing is a key aspect of
modern medicine therefore there is a strong case to add
another review to the existing evidence by examining
where CDSSs have the greatest impact across the prescrib-
ing process. Importantly, as the evidence base grows and
reporting of CDSS and organisational features improves,
a clear enhancement to the current review would be
assessment of the impact of additional system and organ-
isational features on user acceptability and likelihood of
changes in practice in line with CDSS recommendations.
Previous reviews in prescribing have been more restricted
than ours and even the most recent and extensive of these
reviews [9] only targets initiation of therapy and ignores
other prescribing dimensions associated with reviewing/
monitoring existing therapies and stopping therapies.
CDSS interventions are highly complex and their effec-
tiveness is dependent largely on how well they are
designed and implemented. This review was not able to
consider the full impact of factors such as system design,
usability and integration with clinician workflow which
may have influenced the ability of systems to deliver
anticipated prescribing outcomes.
There are also fundamental difficulties in comparing
interventions with diverse objectives, measurement meth-
ods and outcomes. We managed this issue by reportingBMC Health Services Research 2009, 9:154 http://www.biomedcentral.com/1472-6963/9/154
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differences in favour of CDSSs on at least one prescribing
outcome and significant differences on the majority of
prescribing outcomes. Many results were positive, but not
statistically significant, suggesting inadequate sample
sizes and under powering of studies. There is also the pos-
sibility that there is some bias in publishing 'positive'
studies, however many studies included in this review did
not demonstrate significant outcomes in favour of CDSS.
We replicated the summary measure used by Garg et al [1]
(≥ 50% of significant outcomes), but it may be influenced
by the number of outcomes reported and the appropriate-
ness of the outcomes used. For example, the more pre-
scribing outcomes reported, the more difficult it may be to
achieve significant positive effects on the majority of out-
comes measured. However, had we based our findings on
the outcome 'at least one statistically significant outcome
in favour of CDSS', our conclusions would change only
for setting. Using this less stringent measure, we would
have concluded there was no evidence indicating that
CDSS was more effective in institutional compared with
ambulatory care settings.
Many of the studies in this review used outcomes such as
prescribing volume or rates (i.e. number of prescriptions
for a particular drug or drug class). While these measures
are clearly indicative of a desired change in prescribing
practice, previous research has demonstrated that changes
in these measures do not always equate to more 'appropri-
ate' prescribing and better outcomes for all patient sub-
groups. [72,73] Thus, the choice of outcome measures
sensitive to such issues would be of greater benefit in
establishing intended and unintended consequences of
any intervention.
While relatively few studies achieved significant positive
effects on the majority of outcomes, considerably more
studies did demonstrate at least one positive intervention
effect. Many of the studies in this review addressed com-
mon conditions and drugs so any change in outcome may
equate to substantial clinical and fiscal benefits. Further,
while this review did not specifically address the impact of
CDSSs on patient outcomes, if the change in a prescribing
outcome has been demonstrated in randomised control-
led trials to translate into clinical benefit for specific
patient populations (e.g. prescribing medicines to lower
blood pressure or to lower cholesterol levels leads to fewer
myocardial infarctions and strokes) this adds further
weight to the benefits of these interventions.
Further, 'neutral' studies should not necessarily be viewed
negatively. While it was not the intent of the interventions
in this review to establish 'equivalence' it may be worth
considering the benefits of CDSSs in releasing health care
professionals from activities they need not undertake,
such as actively documenting when tests and follow-up
should be performed. Finally, few studies reported unin-
tended negative consequences of CDSS interventions such
as undesirable drug substitution effects. While our review
did not raise any particular concerns about the negative
effect of CDSS, its full impact remains unknown.
Commentary
Limitations notwithstanding, this study has contributed
to the literature by detailing the specific areas within the
prescribing process where CDSSs tend to be more effec-
tive. The most consistently effective approaches used sys-
tem-initiated decision support to fine-tune existing
therapy by making recommendations to improve patient
safety, adjust the dose, duration or form of prescribed
drugs or increase the laboratory testing rates for patients
on long-term therapy. This finding remains consistent
with other literature. Patient safety is a predominant fea-
ture of clinical culture and any system highlighting poten-
tial problems is welcomed and adopted by clinicians.
[1,7] These triggers and reminders simply add safeguards
and enhance continuity and long-term care rather than
posing any threat to professional autonomy.
There is currently insufficient evidence to draw conclu-
sions about the impact of CDSSs with respect to stopping
therapy but changing behaviour in this domain will likely
bring its own challenges. Prescribers may be unwilling to
cease drugs that appear to be working and importantly
doing no harm; and patients are unlikely to request the
drug be stopped. The result is that therapy once started
may be continued long term. Further, reminders for this
kind of clinical review may be perceived as undermining
professional autonomy. [74] Clearly, more studies need
to be conducted in this domain to determine if these
issues apply.
Our findings that system-initiated decision support sys-
tems are more effective than user-initiated systems, and
institutional interventions are more effective than those
conducted in community practice, are not surprising.
Compared with decision support where users are required
to initiate systems manually, automatic prompts are likely
to dovetail more closely with physician workflow and
provide opportunities to work on fine-tuning decisions or
correct shortfalls or errors in care.[1,2] The success of
institutional interventions is likely attributed to the type
of conditions managed in this setting, the stricter controls
on the practices of health care professionals in institu-
tional settings and a potentially greater willingness to
abide by 'externally' imposed rules and management sug-
gestions.
Our finding that multi-faceted interventions appeared no
more effective than CDSS interventions alone conflicts
with a number of other reviews [12-14] and also appearsBMC Health Services Research 2009, 9:154 http://www.biomedcentral.com/1472-6963/9/154
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counterintuitive from a behavioural perspective. How-
ever, in a review of more than 200 studies assessing the
effectiveness of guideline implementation strategies,
Grimshaw and colleagues [75] found multi-faceted inter-
ventions did not appear to be more effective than single
strategy interventions but emphasised the difficultly in
drawing generalisable conclusions about multi-faceted
interventions owing to the large number of different com-
binations used. Further, our results are likely to be con-
founded by the setting in which the interventions
occurred, clinical condition being targeted and the system
design and implementation.
Conclusion
With the ever increasing enthusiasm for, and implementa-
tion of CDSSs in medical practice it is paramount we
determine their benefits and risks in the short, medium
and longer term. As such, it is important to promote the
rigorous testing of these systems to produce high quality
evidence about their clinical and economic impacts. Our
review and others demonstrate CDSSs have merit in sup-
porting specific aspects of the prescribing process. How-
ever, despite the substantial number of CDSS
interventions in this review our understanding of the
impacts of these interventions in particular clinical
domains and settings is still relatively limited. Further,
interventions to date have largely focussed on supporting
clinicians in initiating and monitoring rather than ceasing
therapy.
System developers and policy makers should build on the
consistently effective CDSS approaches identified in this
research such as prompts and alerts incorporating 'do no
harm messages', reminders for patients on long-term ther-
apy and care suggestions for 'at risk' patients. In addition,
further studies are required to determine the relative mer-
its of particular types of CDSS and the factors related to
the successful implementation of these systems. Our
understanding of the impact of CDSSs in clinical practice
would be much enhanced by detailed reporting on the
individual features of the systems, the way in which they
were developed and the specifics of the environment in
which they were deployed.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
SP conceived and designed the study, participated in data
collection and analysis, interpreted findings and drafted
the manuscript. AM contributed to the study design, data
collection and analysis and interpretation of findings. JR
conceived and designed the study and participated in data
collection and analysis and interpretation of findings. IH
contributed to the study design, data collection and anal-
ysis and interpretation of findings. MW contributed to the
study design and interpretation of findings. JR contrib-
uted to the study design and interpretation of findings.
DN conceived and designed the study and participated in
data collection and analysis and interpretation of find-
ings. All authors read and approved the final manuscript.
Additional material
Additional file 1
Full search strategy.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6963-9-154-S1.doc]
Additional file 2
Table S1 - Full summary of results - Initiating treatment. a Other clin-
ical areas include: salicylates or paracetamol in patients with history of GI 
bleed; erythropoietin low Hb; HIV medications; various medications. b 
Other clinical areas include: various medications interacting with warfa-
rin; various conditions in children (e.g. croup, otitis media)
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6963-9-154-S2.doc]
Additional file 3
Table S2 - Full summary of results - Monitoring treatment. c Other 
clinical areas include: hormone treatment for infertility; etretinate for pso-
riasis; HIV medications; various conditions (e.g. epilepsy, gout, diabetes).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6963-9-154-S3.doc]
Additional file 4
Table S3: Key study features and results (Initiating treatment - Before 
drug selection). * Unless otherwise stated, number of patients is close to 
or equal to that specified in the "participants" column, or was not 
reported. + (NS) indicates intervention favoured the CDSS but was not 
statistically significant; - (NS) indicates intervention favoured compari-
son group but was not statistically significant; 0 = no difference between 
groups; ++ indicates intervention favoured CDSS and was statistically sig-
nificant; - - indicates intervention favoured comparator and was statisti-
cally significant; U = unclear. ACE = angiotensin-converting enzyme; 
BMD = bone mineral density; BP = blood pressure; CAD = coronary artery 
disease; CDSS = computerised clinical decision support system; CHD = 
coronary heart disease; CHF = congestive heart failure; CME = continuing 
medical education; CPOE = computerised provider order entry; COPD = 
chronic obstructive pulmonary disease; CVD = cardiovascular disease; 
EMR = electronic medical record; GI = gastro intestinal; GP = general 
practitioner; Hgb = haemoglobin; HIV = human immuno-deficiency 
virus; HMO = Health Maintenance Organisation; IHD = ischemic heart 
disease; LDL = low-density lipoprotein; MI = myocardial infarction; 
NSAIDs = non-steroidal anti-inflammatory drugs; NYHA = New York 
Heart Association; PCP = P carinii pneumonia; RCT = randomised con-
trolled trial; UTI = urinary tract infection;
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6963-9-154-S4.doc]BMC Health Services Research 2009, 9:154 http://www.biomedcentral.com/1472-6963/9/154
Page 12 of 14
(page number not for citation purposes)
Acknowledgements
This project was funded by the National Prescribing Service (NPS) Ltd as 
part of a research partnership with the Universities of Newcastle and New 
South Wales. The NPS established a Study Guidance Group comprising 
representatives from each partner organisation. The Group took oversight 
of the development and implementation of the research. We acknowledge 
the contributions of other Study Guidance Group Members: Dr Bryn 
Lewis, Mr Malcolm Gillies, Mr Adi Smith, Ms Michelle Toms, Ms Michelle 
Sweidan.
References
1. Garg AX, Adhikari NKJ, McDonald H, Rosas-Arellano MP, Devereaux
PJ, Beyene J, Sam J, Haynes RB: Effects of computerized clinical
decision support systems on practitioner performance and
patient outcomes. A systematic review.  JAMA 2005,
293:1223-1238.
2. Kawamoto K, Houlihan CA, Balas EA, Lobach DF: Improving clini-
cal practice using clinical decision support systems: a sys-
tematic review of trials to identify features critical to
success.  BMJ 2005, 330:765.
3. Sintchenko V, Magrabi F, Tipper S: Are we measuring the right
end-points? Variables that affect the impact of computerised
decision support on patient outcomes: a systematic review.
Med Inform Internet Med 2007, 32:225-240.
4 . W a l t o n  R T ,  H a r v e y  E ,  Dovey S, Freemantle N: Computerised
advice on drug dosage to improve prescribing practice.
Cochrane Database Syst Rev 2001:CD002894.
5. Durieux P, Trinquart L, Colombet I, Nies J, Walton R, Rajeswaran A,
Rege Walther M, Harvey E, Burnand B: Computerized advice on
drug dosage to improve prescribing practice.  Cochrane Data-
base Syst Rev 2008:CD002894.
6. Eslami S, Abu-Hanna A, de Keizer NF: Evaluation of outpatient
computerized physician medication order entry systems: a
systematic review.  J Am Med Inform Assoc 2007, 14:400-406.
7. Kaushal R, Shojania KG, Bates DW: Effects of computerized phy-
sician order entry and clinical decision support systems on
medication safety. A systematic review.  Arch Intern Med 2003,
163:1409-1416.
8. Bennett JW, Glasziou PP: Computerised reminders and feed-
back in medication management: a systematic review of ran-
domised controlled trials.  Med J Aust 2003, 178:217-222.
9. Mollon B, Chong J, Holbrook A, Sung M, Thabane L, Foster G: Fea-
tures predicting the success of computerized decision sup-
port for prescribing: A systematic review of randomized
controlled trials.  BMC Medical Informatics & Decision Making 2009,
9:11.
10. Patterson ES, Doebbeling BN, Fung CH, Militello L, Anders S, Asch
SM: Identifying barriers to the effective use of clinical remind-
ers: bootstrapping multiple methods.  Journal of Biomedical Infor-
matics 2005, 38:189-199.
11. Varonen H, Kortteisto T, Kaila M: What may help or hinder the
implementation of computerized decision support systems
(CDSSs): a focus group study with physicians.  Fam Pract 2008,
25:162-167.
12. Grimshaw JM, Shirran L, Thomas R, Mowatt G, Fraser C, Bero L, Grilli
R, Harvey E, Oxman A, O'Brien MA: Changing provider behavior:
an overview of systematic reviews of interventions.  Med Care
2001, 39:II2-45.
Additional file 5
Table S4: Key study features and results (Initiating treatment - After 
drug selection). * Unless otherwise stated, number of patients is close to 
or equal to that specified in the "participants" column, or was not 
reported. + (NS) indicates intervention favoured the CDSS but was not 
statistically significant; - (NS) indicates intervention favoured compari-
son group but was not statistically significant; 0 = no difference between 
groups; ++ indicates intervention favoured CDSS and was statistically sig-
nificant; - - indicates intervention favoured comparator and was statisti-
cally significant; U = unclear. CDSS = computerised clinical decision 
support system; CPOE = computerised provider order entry; COPD = 
chronic obstructive pulmonary disease; CNS = central nervous system; 
CVD = cardiovascular disease; ED = emergency department; EMR = elec-
tronic medical record; GP = general practitioner; HMO = Health Main-
tenance Organisation; ICU = intensive care unit; IV = intravenous; 
MRSA = methicillin-resistant Staphylococcus aureus; NSAIDs = non-
steroidal anti-inflammatory drugs; RCT = randomised controlled trial; 
TCA = tertiary amine tricyclics antidepressant.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6963-9-154-S5.doc]
Additional file 6
Table S5: Key study features and results (Monitoring existing ther-
apy). * Unless otherwise stated, number of patients is close to or equal to 
that specified in the "participants" column, or was not reported. + (NS) 
indicates intervention favoured the CDSS but was not statistically signif-
icant; - (NS) indicates intervention favoured comparison group but was 
not statistically significant; 0 = no difference between groups; ++ indicates 
intervention favoured CDSS and was statistically significant; - - indicates 
intervention favoured comparator and was statistically significant; U = 
unclear. ACE = angiotensin-converting enzyme; BP = blood pressure; ALT 
= alanine aminotransferase; AST = aspartate aminotransferase; CBC = 
complete blood count; CDSS = computerised clinical decision support sys-
tem; CHD = coronary heart disease; CME = continuing medical educa-
tion; CPOE = computerised provider order entry; COPD = chronic 
obstructive pulmonary disease; EMR = electronic medical record; FSH = 
follicle-stimulating hormone; HIV = human immuno-deficiency virus; 
HMO = health maintenance organisation; INR = international normal-
ised ratio; IV = intravenous; LFT = liver function test; LH = luteinizing 
hormone; NYHA = New York Heart Association; PTR = prothrombin time 
ratio; RCT = randomised controlled trial; TSH = thyroid stimulating hor-
mone;
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6963-9-154-S6.doc]
Additional file 7
Table S6: Key study features and results (Stopping treatment). * 
Unless otherwise stated, number of patients is close to or equal to that spec-
ified in the "participants" column, or was not reported. + (NS) indicates 
intervention favoured the CDSS but was not statistically significant; - 
(NS) indicates intervention favoured comparison group but was not sta-
tistically significant; 0 = no difference between groups; ++ indicates inter-
vention favoured CDSS and was statistically significant; - - indicates 
intervention favoured comparator and was statistically significant; U = 
unclear. CDSS = computerised clinical decision support system; CPOE = 
computerised provider order entry; COPD = chronic obstructive pulmo-
nary disease; EMR = electronic medical record; FSH = follicle-stimulating 
hormone; GP = general practitioner; LH = luteinizing hormone; NSAID 
= non-steroidal anti-inflammatory drugs; NYHA = New York Heart Asso-
ciation; RCT = randomised controlled trial.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6963-9-154-S7.doc]
Additional file 8
Table S7: Key differences between the studies included in the current 
review and previous reviews. * Studies were not prescribing focused 
(screening, preventive care/disease management). † Studies addressed 
automated drug dosing studies without decision support. # Review 
excluded studies below a defined quality rating. ‡ Review did not include 
monitoring or ceasing studies.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6963-9-154-S8.doc]BMC Health Services Research 2009, 9:154 http://www.biomedcentral.com/1472-6963/9/154
Page 13 of 14
(page number not for citation purposes)
13. Lu C, Ross-Degnan D, Soumerai S, Pearson S: Interventions
designed to improve the quality and efficiency of medication
use in managed care: a critical review of the literature -
2001-2007.  BMC Health Serv Res 2008, 8:75.
14. Pearson SA, Ross-Degnan D, Payson A, Soumerai SB: Changing
medication use in managed care: A critical review of the
available evidence.  Am J Manag Care 2003, 9:715-731.
15. Bero L, Deane K, Eccles M, Grimshaw J, Gruen R, Mayhew A, Oxman
AD, Pantoja T, Paulsen E, Shepperd S, et al.: Cochrane Effective
Practice and Organisation of Care Group.  About The Cochrane
Collaboration (Cochrane Review Groups (CRGs)) 2009.
16. Ansari M, Shlipak MG, Heidenreich PA, Van Ostaeyen D, Pohl EC,
Browner WS, Massie BM: Improving guideline adherence: a ran-
domized trial evaluating strategies to increase beta-blocker
use in heart failure.  Circulation 2003, 107:2799-2804.
17. Apkon M, Mattera JA, Lin Z, Herrin J, Bradley EH, Carbone M, Holm-
boe ES, Gross CP, Selter JG, Rich AS, Krumholz HM: A randomized
outpatient trial of a decision-support information technol-
ogy tool.  Arch Intern Med 2005, 165:2388-2394.
18. Bloomfield HE, Nelson DB, van Ryn M, Neil BJ, Koets NJ, Basile JN,
Samaha FF, Kaul R, Mehta JL, Bouland D: A trial of education,
prompts, and opinion leaders to improve prescription of
lipid modifying therapy by primary care physicians for
patients with ischemic heart disease.  Qual Saf Health Care 2005,
14:258-263.
19. Cobos A, Vilaseca J, Asenjo C, Pedro-Botet J, Sanchez E, Val A, Tor-
remade E, Espinosa C, Bergonon S: Cost effectiveness of a clinical
decision support system based on the recommendations of
the European Society of Cardiology and other societies for
the management of hypercholesterolemia: report of a clus-
ter-randomized trial.  Dis Manag Health Outcomes 2005,
13:421-432.
20. Demakis JG, Beauchamp C, Cull WL, Denwood R, Eisen SA, Lofgren
R, Nichol K, Woolliscroft J, Henderson WG: Improving residents'
compliance with standards of ambulatory care. Results from
the VA Cooperative Study on Computerized Reminders.
JAMA 2000, 284:1411-1416.
21. Dexter PR, Perkins S, Overhage JM, Maharry K, Kohler RB, McDonald
CJ: A computerized reminder system to increase the use of
preventive care for hospitalized patients.  N Engl J Med 2001,
345:965-970.
22. Eccles M, McColl E, Steen N, Rousseau N, Grimshaw J, Parkin D,
Purves I: Effect of computerised evidence based guidelines on
management of asthma and angina in adults in primary care:
cluster randomised controlled trial.  BMJ 2002, 325:941.
23. Feldstein A, Elmer PJ, Smith DH, Herson M, Orwoll E, Chen C, Aickin
M, Swain MC: Electronic medical record reminder improves
osteoporosis management after a fracture: a randomized,
controlled trial.  J Am Geriatr Soc 2006, 54:450-457.
24. Filippi A, Sabatini A, Badioli L, Samani F, Mazzaglia G, Catapano A, Cri-
celli C: Effects of an automated electronic reminder in chang-
ing the antiplatelet drug-prescribing behavior among Italian
general practitioners in diabetic patients: an intervention
trial.  Diabetes Care 2003, 26:1497-1500.
25. Flottorp S, Oxman AD, Havelsrud K, Treweek S, Herrin J: Cluster
randomised controlled trial of tailored interventions to
improve the management of urinary tract infections in
women and sore throat.  BMJ 2002, 325:367.
26. Fretheim A, Oxman AD, Havelsrud K, Treweek S, Kristoffersen DT,
Bjorndal A: Rational prescribing in primary care (RaPP): a
cluster randomized trial of a tailored intervention.  PLoS Med
2006, 3:e134.
27. Kralj B, Iverson D, Hotz K, Ashbury FD: The impact of computer-
ized clinical reminders on physician prescribing behavior:
evidence from community oncology practice.  Am J Med Qual
2003, 18:197-203.
28. Krall MA, Traunweiser K, Towery W: Effectiveness of an elec-
tronic medical record clinical quality alert prepared by off-
line data analysis.  In Medinfo 2004: Proceedings of the 11th World
Congress on Med Inform; San Francisco, California Edited by: Fieschi M,
Coiera E, Li Y-CJ. IOS Press; 2004:135-139. 
29. Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov
B, Goldhaber SZ: Electronic alerts to prevent venous throm-
boembolism among hospitalized patients.  N Engl J Med 2005,
352:969-977.
30. Kuperman GJ, Teich JM, Tanasijevic MJ, Ma'Luf N, Rittenberg E, Jha A,
Fiskio J, Winkelman J, Bates DW: Improving response to critical
laboratory results with automation. Results of a randomized
controlled trial.  J Am Med Inform Assoc 1999, 6:512-522.
31. Montgomery AA, Fahey T, Peters TJ, MacIntosh C, Sharp DJ: Evalu-
ation of computer based clinical decision support system and
risk chart for management of hypertension in primary care:
randomised controlled trial.  BMJ 2000, 320:686-690.
32. Murray MD, Harris LE, Overhage JM, Zhou XH, Eckert GJ, Smith FE,
Buchanan NN, Wolinsky FD, McDonald CJ, Tierney WM: Failure of
computerized treatment suggestions to improve health out-
comes of outpatients with uncomplicated hypertension:
results of a randomized controlled trial.  Pharmacotherapy 2004,
24:324-337.
33. Overhage JM, Tierney WM, McDonald CJ: Computer reminders
to implement preventive care guidelines for hospitalized
patients.  Arch Intern Med 1996, 156:1551-1556.
34. Paul M, Andreassen S, Tacconelli E, Nielsen AD, Almanasreh N, Frank
U, Cauda R, Leibovici L, Group TS: Improving empirical antibi-
otic treatment using TREAT, a computerized decision sup-
port system: cluster randomized trial.  J Antimicrob Chemother
2006, 58:1238-1245.
35. Roumie CL, Elasy TA, Greevy R, Griffin MR, Liu X, Stone WJ, Wall-
ston KA, Dittus RS, Alvarez V, Cobb J, Speroff T: Improving blood
pressure control through provider education, provider
alerts, and patient education: a cluster randomized trial.  Ann
Intern Med 2006, 145:165-175.
36. Safran C, Rind DM, Davis RB, Ives D, Sands DZ, Currier J, Slack WV,
Makadon HJ, Cotton DJ: Guidelines for management of HIV
infection with computer-based patient's record.  Lancet 1995,
346:341-346.
37. Sequist TD, Gandhi TK, Karson AS, Fiskio JM: A randomized trial
of electronic clinical reminders to improve quality of care for
diabetes and coronary artery disease.  J Am Med Inform Assoc
2005, 12:431-437.
38. Tierney WM, Overhage JM, Murray MD, Harris LE, Zhou XH, Eckert
GJ, Smith FE, Nienaber N, McDonald CJ, Wolinsky FD: Effects of
computerized guidelines for managing heart disease in pri-
mary care.  J Gen Intern Med 2003, 18:967-976.
39. Tierney WM, Overhage JM, Murray MD, Harris LE, Zhou XH, Eckert
GJ, Smith FE, Nienaber N, McDonald CJ, Wolinsky FD: Can compu-
ter-generated evidence-based care suggestions enhance evi-
dence-based management of asthma and chronic
obstructive pulmonary disease? A randomized, controlled
trial.  Health Serv Res 2005, 40:477-497.
40. Flanagan JR, Doebbeling BN, Dawson J, Beekmann S: Randomized
study of online vaccine reminders in adult primary care.
AMIA Annual Symposium Proceedings 1999:755-759.
41. Tang PC, LaRosa MP, Newcomb C, Gorden SM: Measuring the
effects of reminders for outpatient influenza immunizations
at the point of clinical opportunity.  J Am Med Inform Assoc 1999,
6:115-121.
42. Tamblyn R, Huang A, Perreault R, Jacques A, Roy D, Hanley J, McLeod
P, Laprise R: The medical office of the 21st century (MOXXI):
effectiveness of computerized decision-making support in
reducing inappropriate prescribing in primary care.  Can Med
Assoc J 2003, 169:549-556.
43. Smith DH, Perrin N, Feldstein A, Yang X, Kuang D, Simon SR, Sittig
DF, Platt R, Soumerai SB: The impact of prescribing safety alerts
for elderly persons in an electronic medical record. An inter-
rupted time series evaluation.  Arch Intern Med 2006,
166:1098-1104.
44. Shojania KG, Yokoe D, Platt R, Fiskio J, Ma'Luf N, Bates DW: Reduc-
ing vancomycin use utilizing a computer guideline: results of
a randomized controlled trial.  J Am Med Inform Assoc 1998,
5:554-562.
45. Peterson JF, Rosenbaum BP, Waitman LR, Habermann R, Powers J,
Harrell D, Miller RA: Physicians' response to guided geriatric
dosing: initial results from a randomized trial.  Stud Health
Technol Inform 2007, 129:1037-1040.
46. Martens JD, Weijden T van der, Severens JL, de Clercq PA, de Bruijn
DP, Kester ADM, Winkens RAG: The effect of computer
reminders on GPs' prescribing behaviour: a cluster-ran-
domised trial.  Int J Med Inform 2007, 76:S403-S416.
47. Madaras-Kelly KJ, Remington RE, Lewis PG, Stevens DL: Evaluation
of an intervention designed to decrease the rate of nosoco-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Health Services Research 2009, 9:154 http://www.biomedcentral.com/1472-6963/9/154
Page 14 of 14
(page number not for citation purposes)
mial methicillin-resistant Staphylococcus aureus infection by
encouraging decreased fluoroquinolone use.  Infect Control
Hosp Epidemiol 2006, 27:155-169.
48. Kuilboer MM, van Wijk MA, Mosseveld M, van der DE, de Jongste JC,
Overbeek SE, Ponsioen B, van der LJ: Computed critiquing inte-
grated into daily clinical practice affects physicians' behavior
- a randomized clinical trial with AsthmaCritic.  Methods Inf
Med 2006, 45:447-454.
49. Judge J, Field TS, DeFlorio M, Laprino J, Auger J, Rochon P, Bates DW,
Gurwitz JH: Prescribers' responses to alerts during medica-
tion ordering in the long term care setting.  J Am Med Inform
Assoc 2006, 13:385-390.
50. Hulgan T, Rosenbloom ST, Hargrove F, Talbert DA, Arbogast PG,
Bansal P, Miller RA, Kernodle DS: Oral quinolones in hospitalized
patients: an evaluation of a computerized decision support
intervention.  J Intern Med 2004, 256:349-357.
51. Feldstein AC, Smith DH, Perrin N, Yang X, Simon SR, Krall MA, Sittig
DF, Ditmer D, Platt R, Soumerai SB: Reducing warfarin medica-
tion interactions. An interrupted time series evaluation.  Arch
Intern Med 2006, 166:1009-1015.
52. Davis RL, Wright J, Chalmers F, Levenson L, Brown JC, Lozano P,
Christakis DA: A cluster randomized clinical trial to improve
prescribing patterns in ambulatory pediatrics.  PLoS Clinical Tri-
als 2007, 2:e25.
53. Christakis DA, Zimmerman FJ, Wright JA, Garrison MM, Rivara FP,
Davis RL: A randomized controlled trial of point-of-care evi-
dence to improve the antibiotic prescribing practices for oti-
tis media in children [abstract].  Pediatrics 2001, 107:392.
54. Ageno W, Turpie AGG: A randomized comparison of a compu-
ter-based dosing program with a manual system to monitor
oral anticoagulant therapy.  Thromb Res 1998, 91:237-240.
55. Ageno W, Johnson J, Nowacki B, Turpie AGG: A computer gener-
ated induction system for hospitalized patients starting on
oral anticoagulant therapy.  Thromb Haemost 2000, 83:849-852.
56. Burton ME, Ash CL, Hill DP, Handy T, Shepherd MD, Vasko MR: A
controlled trial of the cost benefit of computerized bayesian
aminoglycoside administration.  Clin Pharmacol Ther 1991,
49:685-694.
57. Casner PR, Reilly R, Ho H: A randomized controlled trial of
computerized pharmacokinetic theophylline dosing versus
empiric physician dosing.  Clin Pharmacol Ther 1993, 53:684-690.
58. Feldstein AC, Smith DH, Perrin N, Yang X, Rix M, Raebel MA, Magid
DJ, Simon SR, Soumerai SB: Improved therapeutic monitoring
with several interventions. A randomized trial.  Arch Intern
Med 2006, 166:1848-1854.
59. Fihn SD, McDonell MB, Vermes D, Henikoff JG, Martin DC, Callahan
CM, Kent DL, White RH: A computerized intervention to
improve timing of outpatient follow-up: a multicenter rand-
omized trial in patients treated with warfarin. National Con-
sortium of Anticoagulation Clinics.  J Gen Intern Med 1994,
9:131-139.
60. Koide D, Ohe K, Ross-Degnan D, Kaihara S: Computerized
reminders to monitor liver function to improve the use of
etretinate.  Int J Med Inform 2000, 57:11-19.
61. Lesourd F, Avril C, Boujennah A, Parinaud J: A computerized deci-
sion support system for ovarian stimulation by gonado-
trophins.  Fertil Steril 2002, 77:456-460.
62. Lester WT, Grant RW, Barnett GO, Chueh HC: Randomized con-
trolled trial of an informatics-based intervention to increase
statin prescription for secondary prevention of coronary dis-
ease.  J Gen Intern Med 2006, 21:22-29.
63. Manotti C, Moia M, Palareti G, Pengo V, Ria L, Dettori AG: Effect of
computer-aided management on the quality of treatment in
anticoagulated patients: a prospective, randomized, multi-
center trial of APROAT (Automated PRogram for Oral
Anticoagulant Treatment).  Haematologica 2001, 86:1060-1070.
64. McCowan C, Neville RG, Ricketts IW, Warner FC, Hoskins G, Tho-
mas GE: Lessons from a randomized controlled trial designed
to evaluate computer decision support software to improve
the management of asthma.  Med Inform Internet Med 2001,
26:191-201.
65. Mitra R, Marciello MA, Brain C, Ahangar B, Burke DT: Efficacy of
computer-aided dosing of warfarin among patients in a reha-
bilitation hospital.  Am J Phys Med Rehabil 2005, 84:423-427.
66. Overhage JM, Tierney WM, Zhou XH, McDonald CJ: A randomized
trial of "corollary orders" to prevent errors of omission.  J Am
Med Inform Assoc 1997, 4:364-375.
67. Palen TE, Raebel M, Lyons E, Magid DM: Evaluation of laboratory
monitoring alerts within a computerized physician order
entry system for medication orders.  Am J Manag Care 2006,
12:389-395.
68. Poller L, Wright D, Rowlands M: Prospective comparative study
of computer programs used for management of warfarin.  J
Clin Pathol 1993, 46:299-303.
69. Poller L, Shiach CR, MacCallum PK, Johansen AM, Munster AM,
Magalhaes A, Jespersen J: Multicentre randomised study of com-
puterised anticoagulant dosage.  Lancet 1998, 352:1505-1509.
70. Vadher B, Patterson DL, Leaning M: Evaluation of a decision sup-
port system for initiation and control of oral anticoagulation
in a randomised trial.  BMJ 1997, 314:1252-1256.
71. Verner D, Seligmann H, Platt S, Dany S, Almog S, Zulty L, Halkin H,
Ezra D: Computer assisted design of a theophylline dosing
regimen in acute bronchospasm: serum concentrations and
clinical outcome.  Eur J Clin Pharmacol 1992, 43:29-33.
72. Pearson SA, Soumerai S, Mah C, Zhang F, Simoni-Wastila L, Salzman
C, Cosler LE, Fanning T, Gallagher P, Ross-Degnan D: Racial dispar-
ities in access after regulatory surveillance of benzodi-
azepines.  Arch Intern Med 2006, 166:572-579.
73. Simoni-Wastila L, Ross-Degnan D, Mah C, Gao X, Brown J, Cosler LE,
Fanning T, Gallagher P, Salzman C, Soumerai SB: A retrospective
data analysis of the impact of the New York triplicate pre-
scription program on benzodiazepine use in medicaid
patients with chronic psychiatric and neurologic disorders.
Clin Ther 2004, 26:322-336.
74. Tierney WM, Miller ME, Overhage JM, McDonald CJ: Physician
inpatient order writing on microcomputer workstations:
effects on resource utilization.  JAMA 1993, 269:379-383.
75. Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale
L, Whitty P, Eccles MP, Matowe L, Shirran L, et al.: Effectiveness
and efficiency of guideline dissemination and implementa-
tion strategies.  Health Technol Assess 2004, 8:iii-iv. 1-72
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1472-6963/9/154/pre
pub